Vascular endothelial growth factor(VEGF)slgnalling Is a crlitical regulator of vasculogenesis,angiogenesis,and lymphanglogenesis,processes that are vital for the development of vascular and lymphatic systems,tissue re...Vascular endothelial growth factor(VEGF)slgnalling Is a crlitical regulator of vasculogenesis,angiogenesis,and lymphanglogenesis,processes that are vital for the development of vascular and lymphatic systems,tissue repair,and the maintenance of homeostasis.VEGF ligands and their receptors orchestrate endothelial cell proliferation,migration,and survival,playing a pivotal role in dynamic vascular remodeling.Dysregulated VEGF signaling drives diverse pathological conditions,including tumor angiogenesis cardiovascular diseases,and ocular disorders.Excessive VEGF activity promotes tumor growth,invasion,and metastasis,while insufficient signaling contributes to impaired wound healing and ischemic diseases.VEGF-targeted therapies,such as monoclonal antibodies and tyrosine kinase Inhibitors,have revolutionized the treatment of diseases Involving pathologlcal anglogenesls,offering significant clinical benefits In oncology and ophthalmology.These therapies inhibit angiogenesis and slow disease progression,but they often face challenges such as therapeutic resistan ce,suboptimal efficacy,and adverse effects.To further explore these issues,this review provides a comprehensive overview of VEGF ligands and receptors,elucidating their molecular mechanisms and regulatory networks.It evaluates the latest progress in VEGF-targeted therapies and examines strategies tec address current challenges,such as resistance mechanisms.Moreover,the discussion includes emerging therapeutic strategles such as innovative drug dellvery systems and combination theraples,highllighting the continuous efforts to improve the effectiveness and safety of VEGF-targeted treatments.This review highlights the translational potential of recent discoveries in VEGF biology for improving patient outcomes.展开更多
基金supported by the National Research Foundation of Korea(NRF)grants funded by the Korean Government(MSIP)(RS-2023-00268276 to C.L.,NRF-2023R1A2C3007266,and NRF-2021R1A6A1A03038890 to Y.K.)supported by the Korea Basic Science Institute(National Research Facilities and Equipment Center)grant funded by the Ministry of Education(No.2021R1A6C101A564 and RS-2024-00436674)+1 种基金Industrial Technology Innovation Program(RS-2024-00403190)funded by the Ministry of Trade,Industry&Energy of the Republic of Korea,and Korea Drug Development Fund(RS-2024-00463605).
文摘Vascular endothelial growth factor(VEGF)slgnalling Is a crlitical regulator of vasculogenesis,angiogenesis,and lymphanglogenesis,processes that are vital for the development of vascular and lymphatic systems,tissue repair,and the maintenance of homeostasis.VEGF ligands and their receptors orchestrate endothelial cell proliferation,migration,and survival,playing a pivotal role in dynamic vascular remodeling.Dysregulated VEGF signaling drives diverse pathological conditions,including tumor angiogenesis cardiovascular diseases,and ocular disorders.Excessive VEGF activity promotes tumor growth,invasion,and metastasis,while insufficient signaling contributes to impaired wound healing and ischemic diseases.VEGF-targeted therapies,such as monoclonal antibodies and tyrosine kinase Inhibitors,have revolutionized the treatment of diseases Involving pathologlcal anglogenesls,offering significant clinical benefits In oncology and ophthalmology.These therapies inhibit angiogenesis and slow disease progression,but they often face challenges such as therapeutic resistan ce,suboptimal efficacy,and adverse effects.To further explore these issues,this review provides a comprehensive overview of VEGF ligands and receptors,elucidating their molecular mechanisms and regulatory networks.It evaluates the latest progress in VEGF-targeted therapies and examines strategies tec address current challenges,such as resistance mechanisms.Moreover,the discussion includes emerging therapeutic strategles such as innovative drug dellvery systems and combination theraples,highllighting the continuous efforts to improve the effectiveness and safety of VEGF-targeted treatments.This review highlights the translational potential of recent discoveries in VEGF biology for improving patient outcomes.
